PacMab

PacMab is a clinical-stage biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company utilizes a proprietary site-specific conjugation platform to create therapies with improved stability, homogeneity, and therapeutic index compared to traditional ADCs. Its lead candidate, PMB-101, is a Trop-2-targeted ADC currently in clinical development for various solid tumors, including breast and lung cancers. PacMab's pipeline also includes programs targeting Nectin-4 and HER2, aiming to address unmet needs in cancers such as urothelial and gastric carcinoma. The company operates with a focus on optimizing linker-payload combinations to maximize clinical efficacy and safety while minimizing off-target toxicity.